Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

Sandra K. Thoman, Timothy Burgess(Uniformed Services University of the Health Sciences), Thomas Luke(King Saud bin Abdulaziz University for Health Sciences), Belinda Manukian, Marie‐Carmelle Elie(University of Florida), Evgenia Aga(Harvard University), Darin Ostrander(Johns Hopkins University), Judith Feinberg(Johns Hopkins University), Karen E. King, Carrie A. Holland, Yara A. Park(University of North Carolina at Chapel Hill), Jaime G. Deville(University of California, Los Angeles), Amy Slater(University of the West of England), Nicole M. Iovine(University of Florida), Kanakatte Raviprakash, Shmuel Shoham(Office of Infectious Diseases), Yan Jiang, Charles B. Cairns(Drexel University), Julia A. Metcalf(National Institutes of Health), Monique Huggins, Paul Gaither Jordan, Socorro Pata, Kelsey Brait, Eugenia Quackenbush, Christopher P. Stowell(Massachusetts General Hospital), Pablo Tebas(University of Pennsylvania), Joseph Quinn, Ednan K. Bajwa(Harvard University), Richard T. Davey(National Institutes of Health), Robyn Hoelle, Mary Townsends, Terry Woessner, Kevin Chronowski, Eric C. Feucht(Houston Methodist), Dorothy O’Neil(Social and Scientific Systems (United States)), Janine Danko(Walter Reed National Military Medical Center), Michael D. Hughes(Virginia Tech), Todd E Bell(Texas Tech University), H. Clifford Lane(National Institute of Allergy and Infectious Diseases), K. Alvarez, C. Blanchet, Taylor Hunt, Robert Shawn Wills
The Lancet Respiratory Medicine
May 15, 2017
Cited by 118


Related Papers